ReviewNature reviews. Urology2013
Proposed mechanisms of action for prostate cancer vaccines.
Review in Nature reviews. Urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Journal of immunology research · 2016Pooled it
- Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses.Transgenic research · 2025Article
- Article
- Radium-223 mechanism of action: implications for use in treatment combinations.Nature reviews. Urology · 2019Review
- Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.Frontiers in oncology · 2016Review
- Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Application of radiation technology in vaccines development.Clinical and experimental vaccine research · 2015Review
- Applying biodegradable particles to enhance cancer vaccine efficacy.Immunologic research · 2014Review
- The value of EGFRvIII as the target for glioma vaccines.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2014Review
- Prostate cancer vaccines: Update on clinical development.Oncoimmunology · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is responsible for the deaths of more than 33,000 American men every year. Once this disease has become metastatic, there is no curative treatment. Alternative therapies to chemotherapy and radical prostatectomy are being increasingly explored. Prostate cancer vaccines--which trigger a tumour-specific cytotoxic-T-lymphocyte-mediated immune attack by the patient's immune system--have been investigated in clinical trials with modest, yet encouraging, results. When developing and administering prostate cancer vaccines, it is critical to consider how vital parameters, such as the stage of disease progression and the nature of adjuvant therapies, could influence treatment outcome. Of particular interest are current and future strategies for diminishing the activity of regulatory T lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.